Literature DB >> 6734698

Rapid onset of an increase in caffeine residence time in young women due to oral contraceptive steroids.

E C Rietveld, M M Broekman, J J Houben, T K Eskes, J M van Rossum.   

Abstract

Oral contraceptive steroids increased the residence time of caffeine in 9 young women by a factor of 2. The effect was already manifested during the first cycle 2 weeks after starting oral contraceptive steroids (OCS) and was slightly increased in the second cycle, after 6 weeks on OCS. Toxic effects attributed to oral contraceptive steroids may in part be indirect and due to prolonged retention of absorbed toxic agents to which women are exposed.

Entities:  

Keywords:  Age Factors; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Methods--side effects; Examinations And Diagnoses; Family Planning; Laboratory Examinations And Diagnoses; Laboratory Procedures; Oral Contraceptives--side effects; Population Characteristics

Mesh：

Substances：

Year:  1984        PMID： 6734698     DOI： 10.1007/BF00548769

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  12 in total

1.  Comparison of gas-liquid chromatography with nitrogen-phosphorus selective detection and high-performance liquid chromatography methods for caffeine determination in plasma and tissues.

Authors:  M Bonati; D Castelli; R Latini; S Garattini
Journal:  J Chromatogr       Date:  1979-09-11

2.  Impairment of antipyrine metabolism by low-dose oral contraceptive steroids.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

3.  Effects of an oral contraceptive on hepatic size and antipyrine metabolism in premenopausal women.

Authors:  M Homeida; M Halliwell; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1978-08       Impact factor: 6.875

4.  Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; R Arendt; H R Ochs; R I Shader
Journal:  N Engl J Med       Date:  1982-04-01       Impact factor: 91.245

5.  Influence of sex and oral contraceptive steroids on antipyrine metabolite formation.

Authors:  M W Teunissen; A K Srivastava; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

6.  Inhibition of hepatic drug metabolism by norethindrone.

Authors:  B Field; C Lu; G W Hepner
Journal:  Clin Pharmacol Ther       Date:  1979-02       Impact factor: 6.875

7.  Impaired elimination of caffeine by oral contraceptive steroids.

Authors:  R V Patwardhan; P V Desmond; R F Johnson; S Schenker
Journal:  J Lab Clin Med       Date:  1980-04

8.  Interaction of contraceptive progestins and related compounds with the oestrogen receptor. Part II: Effect on (3H)oestradiol binding to the rat uterine receptor in vitro.

Authors:  J M van Kordelaar; A J Vermorken; C J de Weerd; J M van Rossum
Journal:  Acta Endocrinol (Copenh)       Date:  1975-01

9.  Inhibition of hepatic demethylation of aminopyrine by oral contraceptive steroids in humans.

Authors:  R Herz; H R Koelz; U P Haemmerli; I Benes; A L Blum
Journal:  Eur J Clin Invest       Date:  1978-02       Impact factor: 4.686

10.  The influence of oral contraceptives on the metabolism of methaqualone in man.

Authors:  M Oram; K Wilson; D Burnett
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335
View more
  13 in total

Review 1.  Pharmacokinetic drug interactions with oral contraceptives.

Authors:  D J Back; M L Orme
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 2.  Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.

Authors:  A J Carman; P A Dacks; R F Lane; D W Shineman; H M Fillit
Journal:  J Nutr Health Aging       Date:  2014-04       Impact factor: 4.075

3.  Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination.

Authors:  A Balogh; G Klinger; L Henschel; A Börner; R Vollanth; W Kuhnz
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls.

Authors:  Maria Skaalum Petersen; Jónrit Halling; Per Damkier; Flemming Nielsen; Philippe Grandjean; Pál Weihe; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2006-11-07       Impact factor: 2.953

5.  Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers.

Authors:  Wen-Xing Peng; Huan-De Li; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2003-05-17       Impact factor: 2.953

6.  Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer.

Authors:  Joanne Kotsopoulos; Allison F Vitonis; Kathryn L Terry; Immaculata De Vivo; Daniel W Cramer; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2008-10-21       Impact factor: 2.506

7.  Menstrual cycle effects on caffeine elimination in the human female.

Authors:  J D Lane; J F Steege; S L Rupp; C M Kuhn
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Coffee intake and CYP1A2*1F genotype predict breast volume in young women: implications for breast cancer.

Authors:  H Jernström; M Henningson; U Johansson; H Olsson
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

9.  PCB exposure and in vivo CYP1A2 activity among Native Americans.

Authors:  Edward F Fitzgerald; Syni-An Hwang; George Lambert; Marta Gomez; Alice Tarbell
Journal:  Environ Health Perspect       Date:  2005-03       Impact factor: 9.031

10.  Are the Current Guidelines on Caffeine Use in Sport Optimal for Everyone? Inter-individual Variation in Caffeine Ergogenicity, and a Move Towards Personalised Sports Nutrition.

Authors:  Craig Pickering; John Kiely
Journal:  Sports Med       Date:  2018-01       Impact factor: 11.136
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.